Targeting central DDR mediators, such as poly ADP-ribose polymerase (PARP), checkpoint kinase 1 (CHK1), Ataxia telangiectasia and RAD3-related protein (ATR), Ataxia telangiectasia mutated (ATM), and WEE1, have demonstrated promising therapeutic opportunities in SCLC. The gene discussed is CHEK1; the disease is small cell lung carcinoma.